{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T09:14:54Z","timestamp":1765703694552,"version":"3.48.0"},"reference-count":52,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,8,25]]},"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The widespread use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) by patients with chronic conditions raised early concerns on the potential exacerbation of COVID-19 severity and fatality. Previous studies addressing this question have used standard methods that may lead to biased estimates when analysing hospital data because of the presence of competing events and event-related dependency. We investigated the association of ACEIs\/ARBs\u2019 use with COVID-19 disease outcomes using time-to-event data in a multistate setting to account for competing events and minimise bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Nationwide surveillance data from 119 Belgian hospitals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Medical records of 10 866 patients hospitalised from 14 March 2020to 14 June 2020 with a confirmed SARS-CoV-19 infection and information about ACEIs\/ARBs\u2019 use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary outcome measure<\/jats:title>\n                    <jats:p>Multistate, multivariate Cox-Markov models were used to estimate the hazards of patients transitioning through health states from admission to discharge or death, along with transition probabilities calculated by combining the baseline cumulative hazard and regression coefficients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After accounting for potential confounders, there was no discernable association between ACEIs\/ARBs\u2019 use and transfer to intensive care unit (ICU). Contrastingly, for patients without ICU transfer, ACEIs\/ARBs\u2019 use was associated with a modest increase in recovery (HR 1.07, 95% CI 1.01 to 1.13, p=0.027) and reduction in fatality (HR 0.83, 95% CI 0.75 to 0.93, p=0.001) transitions. For patients transferred to ICU admission, no evidence of an association between ACEIs\/ARBs\u2019 use and recovery (HR 1.16, 95% CI 0.97 to 1.38, p=0.098) or in-hospital death (HR 0.91, 95% CI 0.73 to 1.12, p=0.381) was observed. Male gender and older age were significantly associated with higher risk of ICU admission or death. Chronic cardiometabolic comorbidities were also associated with less recovery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For the first time, a multistate model was used to address magnitude and direction of the association of ACEIs\/ARBs\u2019 use on COVID-19 progression. By minimising bias, this study provided a robust indication of a protective, although modest, association with recovery and survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-053393","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T12:58:02Z","timestamp":1631797082000},"page":"e053393","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Insights into the association of ACEIs\/ARBs use and COVID-19 prognosis: a multistate modelling study of nationwide hospital surveillance data from Belgium"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0096-6238","authenticated-orcid":false,"given":"Jos\u00e9 L.","family":"Pe\u00f1alvo","sequence":"first","affiliation":[{"name":"Unit of Non-Communicable Diseases, Department of Public Health, Institute of Tropical Medicine, Antwerpen, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Els","family":"Genbrugge","sequence":"additional","affiliation":[{"name":"Unit of Non-Communicable Diseases, Department of Public Health, Institute of Tropical Medicine, Antwerpen, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4957-4235","authenticated-orcid":false,"given":"Elly","family":"Mertens","sequence":"additional","affiliation":[{"name":"Unit of Non-Communicable Diseases, Department of Public Health, Institute of Tropical Medicine, Antwerpen, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Sagastume","sequence":"additional","affiliation":[{"name":"Unit of Non-Communicable Diseases, Department of Public Health, Institute of Tropical Medicine, Antwerpen, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne A B","family":"van der Sande","sequence":"additional","affiliation":[{"name":"Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium"},{"name":"Global Health Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc-Alain","family":"Widdowson","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine, Antwerp, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0821-2756","authenticated-orcid":false,"given":"Dominique","family":"Van Beckhoven","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"2025121401101919000_11.9.e053393.1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025121401101919000_11.9.e053393.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002032"},{"key":"2025121401101919000_11.9.e053393.3","doi-asserted-by":"publisher","DOI":"10.1111\/all.14238"},{"key":"2025121401101919000_11.9.e053393.4","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13034"},{"key":"2025121401101919000_11.9.e053393.5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1966"},{"key":"2025121401101919000_11.9.e053393.6","doi-asserted-by":"crossref","first-page":"e00127","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J Virol"},{"key":"2025121401101919000_11.9.e053393.7","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.57278"},{"key":"2025121401101919000_11.9.e053393.8","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000124667.34652.1a"},{"key":"2025121401101919000_11.9.e053393.9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4812"},{"key":"2025121401101919000_11.9.e053393.10","doi-asserted-by":"crossref","unstructured":"Emilsson V , Gudmundsson EF , Aspelund T . Antihypertensive medication uses and serum ACE2 levels. medRxiv 2020;20108738.","DOI":"10.1101\/2020.05.21.20108738"},{"key":"2025121401101919000_11.9.e053393.11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa794"},{"key":"2025121401101919000_11.9.e053393.12","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/eurheartj\/ehaa373","article-title":"Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors","volume":"41","author":"Sama","year":"2020","journal-title":"Eur Heart J"},{"key":"2025121401101919000_11.9.e053393.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-0360-5"},{"key":"2025121401101919000_11.9.e053393.14","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025121401101919000_11.9.e053393.15","first-page":"450","article-title":"[Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV]","volume":"48","author":"Peng","year":"2020","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"2025121401101919000_11.9.e053393.16","doi-asserted-by":"crossref","first-page":"430","DOI":"10.21037\/atm.2020.03.229","article-title":"The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension","volume":"8","author":"Huang","year":"2020","journal-title":"Ann Transl Med"},{"key":"2025121401101919000_11.9.e053393.17","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamacardio.2020.1624","article-title":"Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China","volume":"5","author":"Li","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2025121401101919000_11.9.e053393.18","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s11427-020-1813-0","article-title":"Angiotensin converting enzyme inhibitors and angiotensin receptor blockers improved the outcome of patients with severe COVID-19 and hypertension","volume":"64","author":"Meng","year":"2021","journal-title":"Sci China Life Sci"},{"key":"2025121401101919000_11.9.e053393.19","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202002-0445OC"},{"key":"2025121401101919000_11.9.e053393.20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.120.15143","article-title":"Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study","volume":"76","author":"Yang","year":"2020","journal-title":"Hypertension"},{"key":"2025121401101919000_11.9.e053393.21","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118142","article-title":"The interaction of RAAS inhibitors with COVID-19: current progress, perspective and future","volume":"257","author":"Zhang","year":"2020","journal-title":"Life Sci"},{"key":"2025121401101919000_11.9.e053393.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2006923"},{"key":"2025121401101919000_11.9.e053393.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31030-8"},{"key":"2025121401101919000_11.9.e053393.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008975"},{"key":"2025121401101919000_11.9.e053393.25","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1093\/cid\/ciaa624","article-title":"Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: A nationwide population-based cohort study","volume":"71","author":"Jung","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025121401101919000_11.9.e053393.26","doi-asserted-by":"crossref","unstructured":"Trifiro G , Massari M , Da Cas R . Renin-angiotensin-aldosterone system inhibitors and risk of death in patients hospitalised with COVID-19: a retrospective Italian cohort study of 43,000 patients. Drug Saf 2020:1\u201312 (published Online First: 2020\/08\/28).","DOI":"10.1007\/s40264-020-00994-5"},{"key":"2025121401101919000_11.9.e053393.27","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","article-title":"Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","volume":"126","author":"Zhang","year":"2020","journal-title":"Circ Res"},{"key":"2025121401101919000_11.9.e053393.28","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa433"},{"key":"2025121401101919000_11.9.e053393.29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.11301"},{"key":"2025121401101919000_11.9.e053393.30","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-317393"},{"key":"2025121401101919000_11.9.e053393.31","doi-asserted-by":"crossref","DOI":"10.1038\/s41569-020-0401-0","article-title":"RAAS inhibitors do not increase the risk of COVID-19","volume":"17","author":"Fern\u00e1ndez-Ruiz","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2025121401101919000_11.9.e053393.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2012924"},{"key":"2025121401101919000_11.9.e053393.33","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S256735"},{"key":"2025121401101919000_11.9.e053393.34","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/HJH.0000000000002706","article-title":"Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor\/angiotensin II receptor blocker use during COVID-19: beyond confounding","volume":"39","author":"Cohen","year":"2021","journal-title":"J Hypertens"},{"key":"2025121401101919000_11.9.e053393.35","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-020-01082-z","article-title":"Joint analysis of duration of ventilation, length of intensive care, and mortality of COVID-19 patients: a multistate approach","volume":"20","author":"Hazard","year":"2020","journal-title":"BMC Med Res Methodol"},{"key":"2025121401101919000_11.9.e053393.36","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000004741"},{"key":"2025121401101919000_11.9.e053393.37","doi-asserted-by":"crossref","DOI":"10.1186\/s13690-020-00505-z","article-title":"Rapid establishment of a national surveillance of COVID-19 hospitalizations in Belgium","volume":"78","author":"Van Goethem","year":"2020","journal-title":"Arch Public Health"},{"key":"2025121401101919000_11.9.e053393.38","unstructured":"WHO . COVID-19 and NCDs, 2020. Available: https:\/\/www.who.int\/internal-publications-detail\/covid-19-and-ncds [Accessed 27 Mar 2020]."},{"key":"2025121401101919000_11.9.e053393.39","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000947"},{"key":"2025121401101919000_11.9.e053393.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106144"},{"key":"2025121401101919000_11.9.e053393.41","unstructured":"Survival R package . Available: https:\/\/cran.r-project.org\/web\/packages\/survival\/survival.pdf [Accessed 1 Nov 2020]."},{"key":"2025121401101919000_11.9.e053393.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2010.01.001"},{"key":"2025121401101919000_11.9.e053393.43","unstructured":"Mstate R package . Available: https:\/\/cran.r-project.org\/web\/packages\/mstate\/mstate.pdf [Accessed 1 Nov 2020]."},{"key":"2025121401101919000_11.9.e053393.44","doi-asserted-by":"crossref","unstructured":"Taccone FS , Vangoethem N , Depauw R . The role of organizational characteristics on the outcome of COVID-19 patients admitted to the ICU in Belgium. Lancet Regional Health - Europe 2020:100019.","DOI":"10.1016\/j.lanepe.2020.100019"},{"key":"2025121401101919000_11.9.e053393.45","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15082"},{"key":"2025121401101919000_11.9.e053393.46","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002658"},{"key":"2025121401101919000_11.9.e053393.47","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/ehjcvp\/pvaa056","article-title":"Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality","volume":"6","author":"Cannata","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025121401101919000_11.9.e053393.48","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-021-01992-9","article-title":"Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study","volume":"19","author":"de Abajo","year":"2021","journal-title":"BMC Med"},{"key":"2025121401101919000_11.9.e053393.49","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-2600(20)30558-0","article-title":"Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial","volume":"9","author":"Cohen","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2025121401101919000_11.9.e053393.50","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.25864"},{"key":"2025121401101919000_11.9.e053393.51","doi-asserted-by":"publisher","DOI":"10.1177\/0962280208092301"},{"key":"2025121401101919000_11.9.e053393.52","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2712"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-053393","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T09:10:29Z","timestamp":1765703429000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-053393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":52,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,16]]},"published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1136\/bmjopen-2021-053393"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-053393","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}